HopeStage
Back to all studies
CompletedNCT03292848

Single-Dose Brexpiprazole Safety and Pharmacokinetics in Children

About this titleRead the official source — NCT03292848
Medication studyAges 6–12United StatesADHD
The study in practice

Understand this study

Who was this study for?

Listed age limits: 6 years to 12 years.

Listed locations
Little Rock and 8 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 10, 2017
Recruitment status
Completed
Enrollment listed in the registry
24
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 6 Years to 12 Years
Official registry ID
NCT03292848
Official title
Show the full official title

A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to< 13 Years Old) With Central Nervous System Disorders

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock · Rogers · Long Beach

4 more locations
  • Charlotte
  • Oklahoma City
  • San Antonio
  • Orem

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Brexpiprazole.

Who was this study for?

Listed age limits: 6 years to 12 years.

Want to explore more studies?

Explore studies